We’re also continuing to track the fallout from all the recent FDA controversies.

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...

In this edition of STAT's Health Tech newsletter: the latest on GLP-1 microdosing, AI for medical coding and more.

Metsera said Pfizer and Novo Nordisk both upped their bids to acquire the obesity startup, with Novo’s offer valuing the company for up to $10 billion.

Observers characterized the dismissals, policy reversals, and controversies at the FDA as a soap opera, total disarray, and potentially, unprincipled ...

Fewer pre-teens and adolescents are vaping nicotine these days than in previous years. But a study published yesterday in ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

Sarepta Therapeutics delivered a disastrous third-quarter earnings performance. A long-delayed confirmatory clinical trial of ...

Compass Pathways, which is developing a psilocybin treatment for severe depression, said it now expects an earlier decision ...

Despite no strong evidence of clinical benefit, microdosing GLP-1s will likely continue as a strategy for some to profit off of the popular drug class.

It was the latest shockwave to sweep through an agency beset by all kinds of tumult in recent months. In interviews, ...

In the late 1960s, scientists discovered a miracle drug for Parkinson’s disease — a simple, inexpensive dopamine-replacement ...